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Abstract Honey has potent activity against both antibiotic-
sensitive and -resistant bacteria, and is an interesting agent
for topical antimicrobial application to wounds. As honey is
diluted by wound exudate, rapid bactericidal activity up to
high dilution is a prerequisite for its successful application.
We investigated the kinetics of the killing of antibiotic-
resistant bacteria by RS honey, the source for the
production of Revamil® medical-grade honey, and we
aimed to enhance the rapid bactericidal activity of RS
honey by enrichment with its endogenous compounds or
the addition of antimicrobial peptides (AMPs). RS honey
killed antibiotic-resistantisolates of Pseudomonas aeruginosa,
Staphylococcus epidermidis, Enterococcus faecium, and
Burkholderia cepacia within 2 h, but lacked such rapid
activity against methicillin-resistant S. aureus (MRSA)
and extended-spectrum beta-lactamase (ESBL)-producing
Escherichia coli. It was not feasible to enhance the rapid
activity of RS honey by enrichment with endogenous
compounds, but RS honey enriched with 75 μMo ft h e
synthetic peptide Bactericidal Peptide 2 (BP2) showed
rapid bactericidal activity against all species tested,
including MRSA and ESBL E. coli,a tu pt o1 0 –20-fold
dilution. RS honey enriched with BP2 rapidly killed all
bacteria tested and had a broader spectrum of bactericidal
activity than either BP2 or honey alone.
Introduction
Antibiotic-resistant bacteria pose a very serious threat to
public health. For all antibiotic classes, including the major
last-resort drugs, resistance is increasing worldwide [1, 2].
Even more alarming, very few new antibiotics are being
developed [1, 3], so alternative antimicrobial strategies are
urgently needed.
The potent in vitro activity of honey against antibiotic-
resistant bacteria [4] and its successful application in
the treatment of chronic wound infections not responding
to antibiotic therapy [5]r e s u l t e di nar e v i v a lo ft h ei n t e r e s t
in honey as an antibacterial agent [6–8]. Important
prerequisites for the application of honey as an antimicrobial
agent are reproducible and rapid bactericidal activity [9]a n d
knowledge of its mechanism of action.
Honeys collected from the natural environment, including
Manuka honey, which is used for the production of most
currentlyavailablemedical-grade honeys,showlargevariation
in antibacterial activity [10, 11]. Manuka honey can contain
very high levels of methylglyoxal (MGO), which is regarded
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The honey used as a source for Revamil® medical-grade
honey (RS honey) is produced under standardized conditions
in greenhouses, and is sterilized by gamma irradiation to kill
potentially present bacterial spores. Gamma irradiation is
known not to affect honey bactericidal activity [14].
Revamil® has broad-spectrum, batch-to-batch reproducible
bactericidal activity in vitro. It has been shown that it can
strongly diminish microbial colonization of the human skin
[15]. We have recently identified all major bactericidal factors
in RS honey, i.e., its high sugar concentration, H2O2, low pH,
MGO, and the cationic antimicrobial peptide (AMP) bee
defensin-1 [16].
AMPs are known for their potent, rapid, broad-spectrum
microbicidal activity. Their supposed mechanism of action
is the direct targeting of microbial membranes [17],
although AMPs may also have intracellular targets [18,
19]. A cationic domain of these peptides specifically
interacts with the negatively charged outer surfaces of
microorganisms and a hydrophobic domain is required for
membrane perturbation or penetration, causing either
membrane disruption or translocation into the cell [20,
21]. Some bacteria have evolved mechanisms to reduce
their outer surface negative charge to reduce susceptibility
to AMPs [22]. Since this involves complex biosynthetic
pathways, the risk for rapid resistance development against
AMPs is considered to be low [22].
In the current study, we show that RS honey has potent
bactericidal activity, but this requires prolonged exposure of
the target organisms. RS honey lacks rapid bactericidal
activity against several important antibiotic-resistant wound
pathogens, including methicillin-resistant Staphylococcus
aureus. We were not able to augment the bactericidal
activity of RS honey by enrichment with endogenous honey
bactericidal compounds, but addition of the synthetic AMP
Bactericidal Peptide 2 (BP2) did result in broad-spectrum
rapid bactericidal activity.
Materials and methods
Honey
Unprocessed Revamil source (RS) honey was kindly
provided by Bfactory Health Products (Rhenen, The
Netherlands).
Peptides
BP2 (GKWKLFKKAFKKFLKILAC) and LL-37 were
synthesized at Pepscan Systems (Lelystad, The Netherlands)
using solid-phase Fmoc (9-fluorenylmethoxycarbonyl)
chemistry with a free amine at the N-terminus and a
free amide at the C-terminus. Peptides were high-
performance liquid chromatography (HPLC)-purified
and the purity (>95%) and mass were confirmed by
ion-spray mass spectrometry. The lack of disulfide
formation between free cysteines of BP2 was confirmed
by quadrupole time-of-flight/mass spectrometry (Q-TOF/
MS) analysis.
Microorganisms
Bactericidal activity was assessed against clinical isolates of
methicillin-resistant S. aureus (MRSA), methicillin-resistant
S. epidermidis (MRSE), vancomycin-resistant Enterococcus
faecium (VREF), extended-spectrum beta-lactamase (ESBL)-
producing Escherichia coli (E. coli ESBL) and Pseudomonas
aeruginosa ESBL, and against the Burkholderia cepacia
ATCC 25416 type strain. The oxacillin susceptibility of S.
aureus and S. epidermidis and the vancomycin susceptibility
of E. faecium were determined by Etest (AB Biodisk)
according to the manufacturer’s instructions. ESBLs were
identified as described by Al Naiemi et al. [23].
Determination of H2O2 concentration in honey
Hydrogen peroxide concentrations in honey were determined
quantitatively using a modification of a method described
by White and Subers [24]. Undiluted and ten-fold-diluted
samples of honey (40 μl) were mixed in wells of
microtiter plates with 135 μl reagent, consisting of
50 μg/ml o-dianisidine (Sigma) and 20 μg/ml horseradish
peroxidase type IV (Sigma) in 10 mM phosphate buffer
pH 6.5. o-Dianisidine was freshly prepared as a 1 mg/ml
stock in demineralized water and peroxidase was diluted
from a 10 mg/ml stock in 10 mM phosphate buffer pH 6.5
stored at −2 0 ° C .A f t e r5m i no fi n c u b a t i o na tr o o m
temperature, reactions were stopped by the addition of
120 μl6MH 2SO4 and absorption at 540 nm was
measured. Hydrogen peroxide concentrations were
calculated using a calibration curve of two-fold serial
dilutions of H2O2 ranging from 2,200 to 2.1 μM.
Liquid bactericidal assay
Bactericidal activity was quantitatively assessed in low
protein binding polypropylene microtiter plates (Costar
Corning). Bacteria from logarithmic phase cultures in
trypticase soy broth (TSB; BD Difco) were washed twice
with incubation buffer containing 10 mM phosphate buffer
pH 7.0 supplemented with 1% (v/v) TSB and were
suspended at a concentration of 5×10
6 CFU/ml, based on
optical density. A 50% (v/v) stock solution of honey was
freshly prepared in incubation buffer. For enrichment with
AMPs, an aliquot of 1.2 mM LL-37 or BP2 stock solutions
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peptide, thus, corresponding to the enrichment of undiluted
honey with 75 μM of the respective peptides. Eighty
microliters of diluted honey was mixed with 20 μlo fa
bacterial inoculum containing 5×10
6 CFU/ml, and the
plates were incubated at 37°C on a rotary shaker at
150 rpm. At indicated time points, duplicate 10-μl aliquots
of undiluted and ten-fold serially diluted suspensions were
plated on blood agar. The dilutions were prepared in
incubation buffer containing 0.025% sodium polyanethol
sulfonate (SPS; Sigma), whichneutralizescationic bactericidal
components [25]. Bacterial survival was quantified after
overnight growth at 37°C. The detection level of this assay
is 100 CFU/ml.
To determine the LC99.9 values of LL-37 and
BP2, 25-μl aliquots of two-fold serially diluted peptide
in incubation buffer were prepared in polypropylene
microtiter plates (Costar Corning) and to each of the
wells, 25 μl of a bacterial suspension containing 2×10
6
CFU/ml was added. After 2 h of incubation on a rotary
shaker at 150 rpm at 37°C, triplicate 10-μla l i q u o t sw e r e
plated on blood agar plates. The plates were inspected for
growth after 24 h. LC99.9 was defined as the lowest
concentration of peptide which killed >99.9% of the
inoculum of 10
6 CFU/ml after 2 h.
Partial purification of bee defensin-1
We previously demonstrated that bee defensin-1 is the only
bactericidal factor in the >5-kDa fraction of RS honey [16].
To prepare a >5-kDa fraction, 15 ml of 20% (v/v) honey
was centrifuged in a 5-kDa molecular weight cut-off
Amicon Ultra-15 tube (Millipore) at 4,000g for 45 min at
room temperature. The >5-kDa retentate was subsequently
washed three times in the filter tube with 15 ml of
demineralized water and concentrated to 0.3 ml.
Results
Kinetics of the bactericidal activity of RS honey
We determined the kinetics of the bactericidal activity of
different dilutions of RS honey against various antibiotic-
resistant pathogens. RS honey at a concentration of 40%
(v/v) reduced the survival of MRSE, VREF, ESBL-
producing P. aeruginosa,a n dBurkholderia cepacia to
undetectable levels within 2 h, while similar activity
against MRSA and ESBL E. coli r e q u i r e d6ho f
incubation (Fig. 1). RS honey at a concentration of 20%
killed B. cepacia within 4 h of incubation, while activity
against all other bacteria required 24 h of incubation
(Fig. 1). RS honey diluted to 10% killed MRSA and
MRSE after 24 h, but lacked activity against all other
bacteria tested (Fig. 1).
Even in undiluted RS honey, the survival of MRSA
w a sn o ta f f e c t e dw i t h i n2h( F i g .2) of incubation and
the numbers of CFU of E. coli ESBL were only reduced
by 2.3-log. After 24 h incubation in undiluted honey,
the survival of E. coli was reduced to undetectable levels,
but the numbers of CFU of MRSA were only reduced by
1-log (Fig. 2). In summary, RS honey did not rapidly kill
MRSA and E. coli ESBL, and rapid activity against all
other species tested was abolished upon dilution of the
honey to ≤20%.
H2O2 concentration required for the rapid killing of MRSA
Since MRSA and E. coli ESBL were not rapidly killed by
RS honey, we assessed whether the endogenous concen-
trations of bactericidal compounds in RS honey might be
too low for rapid activity. The dilution of RS honey to 30%
was optimal for H2O2 accumulation, resulting in maximal
concentrations of 22.5±1.3 μg/ml and 148.4±27.8 μg/ml
H2O2 after 2 and 24 h, respectively (Fig. 3a). In incubations
not containing honey but only H2O2, 3,200 μg/ml H2O2
was required to kill MRSAwithin 2 h (Fig. 3b). This is 142
times the concentration of H2O2 that maximally accumu-
lated in RS honey after a similar 2-h incubation period,
indicating that the H2O2 concentration in honey is far too
low for rapid activity against MRSA. In view of possible
toxicity (see the Discussion section), it is not feasible to
increase the concentration of H2O2 in honey to the level
required for rapid killing. For similar reasons, we did not
assess the enrichment of RS honey with MGO.
Bee defensin-1 concentration required for the rapid killing
of MRSA
Next, we assessed the contribution of bee defensin-1 to the
rapid bactericidal activity of RS honey. At the concentration
present in undiluted RS honey, bee defensin-1 effectively
killed Bacillus subtilis, a highly bee defensin-1-susceptible
organism [16], within 2 h (Fig. 4a). However, this peptide
had no substantial activity against MRSA, E. coli ESBL, or
VREF (Fig. 4a). Even at an eight-fold higher concentration,
bee defensin-1 reduced the numbers of CFU of MRSA after
2 h by only 1-log (Fig. 4b), indicating that it also was not
feasible to enhance the rapid bactericidal activity of RS
honey by increasing the concentration of bee defensin-1.
Enhanced rapid bactericidal activity of LL-37-enriched
honey
We subsequently assessed the potential of LL-37, a broad-
spectrum human AMP expressed in neutrophils and various
Eur J Clin Microbiol Infect Dis (2011) 30:251–257 253epithelial cells [26, 27], to enhance the rapid bactericidal
activity of honey. RS honey was enriched with ten-fold
excess (75 μM) of the concentration of LL-37 required to
reduce the survival of MRSA to undetectable levels
(Fig. 5a). The lethal concentration of LL-37 for 99.9% of
the inocula (LC99.9)ofMRSAandE. coli in 2-h incubations
were 7.5 and 1.9 μM, respectively (Fig. 5a). The enrichment
of RS honey with LL-37 substantially improved the activity
against E. coli ESBL and VREF, but not against other
bacteria tested (Fig. 5b). LL-37-enriched honey retained
bactericidal activity against E. coli ESBL and VREF up to
20-fold dilution, which was a major improvement compared
to non-enriched honey (Fig. 5b). The LC99.9 of LL-37 in
honey, however, was four-fold higher than in incubation
buffer (Fig. 5b), indicating that honey inhibited LL-37.
Inhibition was even more clear from the tests with MRSA,
MRSE, and P. aeruginosa.E n r i c h m e n tw i t hL L - 3 7d i dn o t
substantially improve the activity of honey, while LL-37
alone effectively killed these bacteria (Fig. 5b).
Enhanced bactericidal activity of BP2-enriched honey
The synthetic AMP BP2 has potent activity in physiological
salt concentrations and in plasma, and is effective in vivo
in a mouse model of biomaterial-associated infection
[28]. The LC99.9 concentrations of BP2 for MRSA and E.
coli in 2-h incubations were 1.9 and 3.8 μM, respectively
(Fig. 6a). RS honey enriched with ten-fold excess (75 μM)
of the concentration of BP2 required to reduce the survival
of MRSA to undetectable levels (Fig. 6a) retained
bactericidal activity against all bacteria tested up to 20-fold
dilution, except for P. aeruginosa (Fig. 6b), which was
killed by up to a ten-fold dilution of this enriched RS
honey (Fig. 6b). Non-enriched RS honey lacked rapid
bactericidal activity for all bacteria tested when diluted
more than 2.5-fold.
The activity of BP2 against E. coli ESBL and VREF was
not inhibited in honey (Fig. 6b). The killing of MRSA,
MRSE, and P. aeruginosa ESBL required 2–4-fold higher
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Fig. 2 Bactericidal activity of undiluted honey against methicillin-
resistant Staphylococcus aureus (MRSA) (white bars) and extended-
spectrum beta-lactamase (ESBL)-producing Escherichia coli (gray
bars). Inocula of approximately 10
5 CFU in 4 μl were added to 0.5 ml
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254 Eur J Clin Microbiol Infect Dis (2011) 30:251–257concentrations of BP2 in honey than in buffer (Fig. 6b).
This indicates a slight reduction of BP2 activity in honey,
but markedly less than the observed inhibition of LL-37 in
honey. We conclude that enrichment with 75 μM BP2
markedly enhanced the rapid bactericidal activity of RS
honey.
Discussion
The potent activity against antibiotic-resistant pathogenic
bacteria makes honey an interesting agent to treat topical
infections not responding to antibiotics. Ideally, honey used
for such applications should have rapid and broad-spectrum
bactericidal activity. In addition, honey should remain
active upon dilution, since honey will be rapidly diluted at
the wound interface due to its hygroscopic characteristics
and the presence of wound exudate.
RS honey has reproducible, broad-spectrum bactericidal
activity in vitro and effectively reduces the microbial
colonization of human skin [15]. Our present results,
however, show that the activity of this honey against the
major wound-infecting pathogens MRSA and E. coli ESBL
is not rapid. Honey does have rapid activity against P.
aeruginosa, E. faecium, and S. epidermidis, but this activity
is lost when RS honey becomes diluted. Of note, B.
cepacia, an otherwise notoriously antibiotic-resistant
pathogen, proved to be the most honey-susceptible organism.
Enhancement of the activity of RS honey with its endogenous
microbicidal compounds appeared not to be feasible, but
addition of the cationic AMP BP2 did increase the activity to
the desired levels.
We recently identified all bactericidal factors in RS
honey using an approach of successive neutralization of
individual factors combined with activity-guided isolation
of factors responsible for residual bactericidal activity [16].
Thus, we determined that the high sugar concentration,
H2O2 production, MGO, the low pH, and bee defensin-1
were responsible for the bactericidal activity of RS honey.
In order to enhance the rapid bactericidal activity of RS
honey, we first assessed the potential of H2O2 and of bee
defensin-1. Upon the dilution of honey, H2O2 is produced
by the glucose oxidase enzyme from the bees [24, 29]. The
production of H2O2 was highest in RS honey diluted to
30%, in which 22.5 and 148 μg/ml accumulated after 2 and
24 h, respectively. In a study with 90 different honeys, 12±
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using the >5-kDa fraction of RS honey in which bee defensin-1 is the
only antibacterial factor present [16]. a Bactericidal activity of bee
defensin-1 against various bacteria was assessed after 2 h (gray bars)
or 24 h (hatched bars) of incubation at the concentration of this
peptide as present in undiluted RS honey. As a control, bacteria were
incubated for 2 h in incubation buffer (white bars). b Bactericidal
activity of concentrated bee defensin-1 against MRSA after 2 h of
incubation. Incubation in buffer was used as a control
Eur J Clin Microbiol Infect Dis (2011) 30:251–257 25519μg/mlhydrogenperoxide(range0–72μg/ml)accumulated
in honey diluted to 20% (w/v) after 4 h [24], indicating that
RS honey produces relatively high levels of H2O2.
MRSA is highly susceptible to H2O2-mediated killing by
RS honey upon incubation for 24 h [16]. The killing of
MRSA within 2 h by H2O2 in the absence of honey
required a concentration as high as 3,200 μg/ml H2O2
(corresponding to a 0.32% (w/v) solution). Wound cleansing
witha 3%(w/v) solutionofH2O2 has been a clinical practice,
but at this concentration, H2O2 is toxic to human cells and
skin tissue, and tissue exposure can result in delayed wound
healing [30–32] . Although the concentration of H2O2
required to kill MRSA was about ten-fold lower than the
concentration used for wound cleansing, we did not consider
increasing the levels of H2O2 as a possibility to improve the
rapid bactericidal activity of RS honey.
Bee defensin-1 (also referred to as royalisin [33]) is a 51-
residue AMP identified in honey bee hemolymph, royal
jelly, and in honey [16, 33, 34]. Because of its complicated
folding with three intramolecular cysteine bonds, the
synthetic production of bee defensin-1 is not possible and
recombinant production would be highly challenging. Bee
defensin-1 effectively kills B. subtilis but lacks activity
against all other bacteria tested at a concentration equivalent
to that in undiluted honey. Even at an eight-fold higher
concentration, bee defensin-1 only slightly reduced the
survival of MRSA. The narrow spectrum of its bactericidal
activity renders bee defensin-1 unsuited for enhancement of
the bactericidal activity of honey.
MGO is present in RS honey at a relatively low
concentration (0.25 mM) compared to the concentrations
reported for Manuka honey (up to 16.1 mM) [12]. MGO is
a reactive metabolite that can exert toxic effects by the
direct inhibition of enzymes, by genomic modifications
resulting in carcinogenesis, and by protein modifications
resulting in the formation of advanced glycation end
products [35]. The latter are believed to be the main
determinants for pathological effects related to diabetes [36,
37]. Because of the concerns regarding the potential
toxicity of MGO, we did not pursue to augment the activity
of RS honey with this compound.
Other honey bactericidal factors are the high sugar
concentration and low pH. Honey is a super-saturated
sugar solution, so it is not possible to further increase its
sugar concentration. RS honey has a pH of 3.2, which is at
the lower end of the pH range found for honeys (3.2–4.5)
[16]. Even such a low pH only contributed to the activity
against B. subtilis after 24 h of incubation, and not to the
activity against other bacterial species [16]. Therefore, the
sugar concentration and low pH were not suited as factors
for the enhancement of the bactericidal activity of honey.
In contrast to bee defensin-1, most AMPs have broad-
spectrum bactericidal activity. The human α-helical AMP
LL-37 is one of the best characterized AMPs [38–41].
Despite its potent activity in incubation buffer, LL-37 was
strongly inhibited in the presence of honey. BP2 is a
synthetic AMP with very rapid broad-spectrum micro-
bicidal activity, which is retained in plasma and in
physiological salt solution [28]. BP2 also effectively kills
S. epidermidis in vivo, in a murine model of biomaterial-
associated infection [28], indicating its potential for clinical
application. The activity of BP2 against E. coli ESBL and
VREF was not inhibited in honey, and activity against
MRSA, MRSE, and P. aeruginosa ESBL required only
slightly higher (2–4-fold) concentrations in honey than in
buffer. Thus, BP2 was certainly suited for the enrichment
of honey.
B. cepacia is notorious for its intrinsic resistance against
antibiotics [42, 43] and AMPs [44], and is, indeed, not
susceptible to LL-37 [44] or to BP2 [28]. Our results
demonstrate, however, that B. cepacia is relatively susceptible
to honey compared to other tested bacteria, which is in
accordance with the findings of Cooper et al. [45]. Not
surprisingly, the addition of BP2 to RS honey did not
enhance the bactericidal activity against B. cepacia (not
shown).
In summary, we were able to enhance the bactericidal
activity of honey by enrichment with the AMP BP2. BP2-
enriched RS honey had rapid bactericidal activity up to a
high dilution against all bacteria tested and had a broader
spectrum of bactericidal activity than either agent alone.
This offers prospects for the development of clinically
applicable honey-based antimicrobials with rapid and
broad-range microbicidal activity.
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